Physician profile
Vikram Patney
NPI 1699744235
$1,648.00
in general payments reported to CMS, 2019-2025
24 companies · $75.69 in 2025
The $75.69 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $26.64 · 2021: $41.56 · 2022: $55.06 · 2023: $685 · 2024: $468 · 2025: $75.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $299.26 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $140.59 | 2021-2023 | |
| Vifor Pharma, INC. | $130.33 | 2019-2023 | Veltassa |
| Abbvie INC. | $122.26 | 2023-2024 | |
| Glaxosmithkline, LLC. | $112.84 | 2023 | |
| Lilly USA, LLC | $100.12 | 2023-2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.70 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $75.13 | 2023-2024 | |
| Akebia Therapeutics INC | $71.11 | 2019-2020 | |
| Amgen INC. | $70.63 | 2019-2025 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $56.63 | 2020-2025 | Farxiga |
| Calliditas Therapeutics US INC. | $52.94 | 2024 | |
| Mallinckrodt Hospital Products INC. | $51.63 | 2024 | Terlivaz |
| Opko Pharmaceuticals, LLC | $40.50 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $34.76 | 2023 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $34.73 | 2023 | Gattex |
| Novo Nordisk INC | $30.16 | 2024-2025 | Rybelsus, Ozempic |
| Horizon Therapeutics Plc | $25.04 | 2023 | Krystexxa |
| Scpharmaceuticals INC. | $23.41 | 2024 | |
| Shield Therapeutics INC | $23.03 | 2023 | Accrufer |
| Kyowa Kirin, INC. | $21.84 | 2024 | Crysvita |
| Alnylam Pharmaceuticals INC. | $21.29 | 2024 | Givlaari |
| Cumberland Pharmaceuticals, INC. | $17.87 | 2019 | |
| Mallinckrodt Enterprises LLC | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Patney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.